Roche completes acquisition of ARIUS Sep 24, 2008
- Gains access to new screening platform for antibody therapeutics BASEL, Switzerland, Sept. 24 /CNW/ - Roche (SWX: ROG) announced today that it has completed the acquisition of 100% of the issued and outstanding shares and warrants of ARIUS Research (TSX: ARI) ... ARIUS is the developer of a proprietary antibody platform called FunctionFIRST(TM), which rapidly identifies and selects antibodies based on their functional ability to affect disease before progressing into clinical development ...... (Canada Newswire)
Possible marker for ovarian cancer found Sep 24, 2008
D., the director of the lab where Li works, calls the discovery important because TEM1 will let researchers and doctors eventually image, or visualize, the cancer "and also target it therapeutically through a TEM1 antibody.". "I think it's very exciting that people are starting to get closer to a test that might be able to be used for screening," says Barbara Goff, M.D., director of gynecologic oncology at the University of Washington School of Medicine. (CNN -- Health)
Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration Sep 23, 2008
OSLO, September 23 /PRNewswire/ -- Affitech AS, the Norwegian human antibody therapeutics company, today announced that it has accomplished the second milestone in its research and licensing collaboration with Roche to produce fully human recombinant antibodies against an unnamed oncology target. Affitech has successfully used its MBAS (Molecule Based Antibody Screening) system that included its proprietary antibody library and high throughput screening technology to identify several fully human... (PR Newswire)
Key PDL patents under fire Sep 23, 2008
PDL s Queen patents named for company co-founder Cary Queen are for its antibody humanization patents, which also are licensed to companies like (NYSE: DNA) for the anti-cancer drug Avastin. The patents expire in the United States in 2014. (San Francisco Business Times, CA)
Cellerant signs $13.5M contract for radiation treatment Sep 23, 2008
a biotechnology company developing hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, said Monday it was awarded a $13. 5 million government contract. (San Jose Business Journal, CA)
XOMA to Webcast Analyst and Investor Event 'Interleukin-1 Blockers: Unlocking Their Potential in Diabetes and Beyond' On September 25 Sep 22, 2008
Sept. 22, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (NasdaqGM: - ), a leader in the discovery and development of antibody therapeutics, announced today that the company will host a live web cast of its analyst and investor event on September 25, 2008 at 5:00 PM Eastern ... The speakers will also highlight interim data from two Phase 1 studies of XOMA 052, an anti-IL-1 beta antibody, in type 2 diabetes ... XOMA discovers, develops and manufactures therapeutic antibody agents designed to treat... (Primezone Releases)
New Pegloticase and Treatment Failure Gout Data to be Featured in Six Abstracts At American College of Rheumatology 72nd Annual Scientific Meeting Sep 22, 2008
Pegloticase treated patients with the highest anti-pegloticase antibody titers failed to maintain normalization of plasma uric acid. Additionally, pegloticase treated patients with the high anti-pegloticase antibody titers had a higher incidence of infusion-related reactions. (Primezone Releases)
The Role of B Lymphocytes in Autoim... Sep 21, 2008
This study is the direct result of a 5-year investigation into the role of Toll-like receptors in antibody production ... In their new study the Yale researchers found that this ability of self antigens to react with the Toll-like receptor stimulates B cells to begin autoantibody production ... Consequently, an ongoing process occurs in which autoantibody production persists. (Suite101.com)
Mother's Flu Shot Protects Newborns Sep 20, 2008
19, 2008) Newborns can be protected from seasonal flu when their mothers are vaccinated during pregnancy, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health. The researchers observed a 63 percent reduction in proven influenza illness among infants born to vaccinated mothers while the number of serious respiratory illnesses to both mothers and infants dropped by 36 percent. (Science Daily)
Researchers Invigorate 'Exhausted' Immune Cells Sep 19, 2008
In their study, published online September 15 in the Proceedings of the National Academy of Sciences (PNAS), Wistar Institute investigators and colleagues report that using an antibody to block the receptor, known as programmed death-1 (PD-1), dramatically restored immunity in chronically infected mice ... Wherry's continuing research on PD-1 has provided the groundwork for developing antibody therapies that inhibit the receptor ... In follow-up experiments, they found that if they blocked PD-1... (Science Daily)
Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway Sep 18, 2008
The company's two preclinical programs, a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases, continue to hold promise and to generate strong scientific and commercial interest ... Trillium has two preclinical programs targeting the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer and a CD200Fc fusion protein for the treatment of autoimmune and... (Canada Newswire)
Celiac Disease Sep 18, 2008
Gluten Free Diet May Not Offer Protection. Gluten is in many processed foods, including meats (canned and cold cuts), salad dressings, condiments, soups, flavored yogurt, and even herbal teas. (Suite101.com)
An 'HIV-test' Equivalent For Early Detection Of Lung Cancer Sep 18, 2008
D., and colleagues at the Hutchinson Center and University of Michigan found that just as the immune system reacts to the presence of HIV by producing an antibody response, which indicates a person is HIV positive, it also mounts a response against specific antigens, or proteins, produced by cancerous lung tumors in their early stages of development. "This kind of immune response won't necessarily kill the tumor, but it can act as a canary in a coal mine, signaling lung cancer at an early stage,... (Science Daily)
Human rabies vaccines harder to find this year Sep 18, 2008
They should also receive a dose of an antibody that provides immediate, but temporary, protection. But this summer and fall around most of the country doctors are being forced to be choosier about who gets vaccinated for rabies. (Scripps Howard News Wire)
CBDM.T®, The Market and Business Intelligence Company Reviews The Biomanufacturing Market Sep 15, 2008
Microbial fermentation is used when smaller and less complex molecules with no post-translational modifications are required (peptides, small proteins, enzymes and antibody fragment). Mammalian cell culture is definitely dominating the manufacturing of complex proteins (glycosylated) and monoclonal antibodies. (Yahoo News -- Press Releases)
Slim antibody pills next big thing? Sep 13, 2008
Slim antibody pills next big thing ... Slim antibody pills next big thing ... LONDON: GlaxoSmithKline Plc's head of biotech research is excited about a new generation of "slimline" antibody medicines that may be successors to current blockbusters such as Avastin and Rituxan. (India Times, India)
Program makes hygiene exciting for kids Sep 13, 2008
com will teach elementary school children how to wash their hands properly to prevent the spread of the antibody resistant germ staphylococcus aureus, also known as MRSA.. Diane Mayberry, infection prevention specialist at Timpanogos Regional Hospital, said doctors are working to bring the Web site to local school districts and health fairs. (The Daily Universe, UT)
A novel receptor - ligand pathway for entry of Francisella tularensis in monocyte-like THP-1 cells: interaction between surface nucleolin and bacterial elongation factor Tu Sep 13, 2008
A specific polyclonal murine antibody was raised against recombinant LVS EF-Tu. By fluorescence and electron microscopy experiments, we found that a fraction of EF-Tu could be detected at the bacterial surface. (BioMed Central)
AstraZeneca Acquires Rights From SBI to Antibody for Auto-Immune Disease Sep 12, 2008
Sept. 12 (Bloomberg) -- , the U.K.'s second- largest drugmaker, bought the global rights from Japan's to develop and sell an experimental antibody to treat a type of auto-immune disease ... AstraZeneca will begin development by testing the antibody on monkeys, he said. (Bloomberg -- Japan)
Trubion Pharmaceuticals wins European patent fight round Sep 12, 2008
According to the Seattle biopharmaceutical company (NASDAQ: TRBN), the Opposition Division of the European Patent Office has revoked a and patent for a rheumatoid arthritis treatment antibody. Trubion, and other parties, argued that the patent as granted did not meet the requirements for patentability under European rules. (Puget Sound Business Journal, WA)
An Infant with Congenital Deafness, Lethargy, and Hypothermia Sep 11, 2008
The mother had received prenatal care with normal screening laboratory tests, including a positive test result for antibody to rubella and negative test results for group B streptococcus, rapid plasma reagin, hepatitis C, and human immunodeficiency virus. The prenatal course was uncomplicated; the mother had no fever or other symptoms of infection, and there was no change in fetal movement. (New England Journal of Medicine)
Bacteria glue helps fight superbugs Sep 11, 2008
LONDON: A sticky glue secreted by drug-resistant bacteria could help scientists develop an effective vaccine against superbugs", US researchers told a conference on Wednesday. The sticky substance is a complex sugar called PNAG which the researchers said was a promising vaccine target because animal studies have shown it produces a protective immune response when manipulated chemically. The bacteria produces the substance when growing a biofilm that protects them from antibiotics, Gerald Pier... (India Times, India -- Health/Science)
Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche Sep 10, 2008
TORONTO, Sept. 9 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that RiskMetrics ISS Canada, Canada's leading independent proxy firm, has indicated that they have no objection to the transaction, and are recommending that ARIUS shareholders and warrant holders vote FOR the proposed plan of arrangement whereby Roche will acquire all of ARIUS' outstanding shares and warrants ...... (PR Newswire)
Affitech Appoints Dr. Keith McCullagh as Chairman Sep 9, 2008
OSLO, Norway, September 9 /PRNewswire/ -- Affitech AS, the Norwegian antibody therapeutics company, today announced that it has appointed Dr Keith McCullagh as non-executive Chairman of its Board of Directors ... Mr Broymer welcomed Dr McCullagh's appointment and said: "I am delighted that Keith McCullagh has agreed to take over from me as Affitech's new chairman. He has an outstanding entrepreneurial track record in the biopharmaceutical industry, most recently at Santaris Pharma in Denmark,... (PR Newswire)
Venomous clues in lung bug battle Sep 8, 2008
"If it is hard for an antibiotic with small molecules to be taken up by a biofilm, then it may be just as hard for an antibody to do it. "The acid test is what happens in the human. " Bookmark with: SEE ALSO 31 Mar 08 | Health 07 Jul 07 | Health 27 Jan 06 | Health RELATED INTERNET LINKS The BBC is not responsible for the content of external internet sites E-MAILED Schoolboy busker wows crowds 'Climate crisis' needs brain gain Thai PM rules out military coup Is this the world's oldest busker?... (BBC News)
Arteries From Distinct Regions Of The Body Have Unique Immune Functions Sep 7, 2008
10, 2001) New York University School of Medicine researchers have found, for the first time, an antibody that destroys an essential component of the blood called platelets. The novel finding may open new. (Science Daily)
Why Campbelltown completes Newtown Sep 6, 2008
Yet, he asserted, "it is not too far-fetched to say that each was an indispensable antibody for the other's healthy existence". Kim Huynh is a lecturer in politics and international relations at the Australian National University. (Sydney Morning Herald -- Opinion)
UPDATE 1-Merck KGaA, Ablynx sign up to $484 mln drug deal Sep 4, 2008
LONDON, Sept 4 (Reuters) - Belgium's Ablynx NV (ABLX.BR: , , , ), which is using llamas to develop next generation antibody drugs, has signed a drug development deal with Germany's Merck KGaA (MRCG.DE: , , , ) worth up to 335 million euro ($484 million) ... The Ghent-based company plans to catch a new wave in antibody medicine by capitalising on a quirk of nature, which means llamas and camels possess an unusual type of antibodies that are much smaller than those in humans and other animals ...... (Reuters)
Early Onset Gene For Inflammatory Bowel Diseases Identified Sep 4, 2008
Kugathasan notes that a related protein, tumor necrosis factor alpha, is the target of an existing antibody treatment for inflammatory bowel disease. This suggests that antibodies to TNFRSF6B could also be helpful in controlling the disease, he says. (Science Daily)
Emergent BioSolutions wins $24.3M to fight anthrax Sep 4, 2008
The bulk of the money, $20 million, would be used to complete the first phase of human testing for the antibody-based drug, which is designed to treat people who have already been exposed to anthrax ... Emergent did not invent this particular antibody approach it bought the rights to the experimental drug from Avanir Pharmaceuticals in March 2008. (Washington Business Journal, DC)
Pfizer Gambles On Russian Alzheimer's Pill Sep 4, 2008
In July, Elan and Wyeth unveiled anemic initial trial results for a widely touted antibody against the brain plaques thought to be a culprit in the disease. Undeterred, Pfizer (nyse: - - ) is plunging ahead with a big bet on an obscure experimental Alzheimer's drug from the biotech firm Medivation (nasdaq: - - ), based in San Francisco. (Forbes -- Business)
Flu Shot Does Not Reduce Risk Of Death, Research Shows Sep 1, 2008
(July 11, 2008) A new study in the journal Psychophysiology reveals that men, but not women, vaccinated in the morning produced a better peak antibody response to both hepatitis A and the influenza. (Feb. (Science Daily)
Growth factor predicts poor outcome in breast cancer Aug 31, 2008
Currently, the Breast Center is studying the effects of an IGF receptor antibody combined with a drug called exemestane (Aromasin or an aromatase inhibitor that blocks estrogen production) in postmenopausal women. One group of women take the combination and the other takes exemestane. (EurekAlert!)
Preliminary Final Report Aug 29, 2008
Final Clinical Study Report (CSR) of CVacTM confirms findings - shows that there was a statisticallysignificant clinical benefit in patients treated with CVacTMGAP analysis received for US FDA INDLeading cancer/oncology and immunology expert Professor Ian Frazer engaged as a scientificadvisor to the Company Australian & US Patents granted to Prima's subsidiary, Oncomab Pty LtdSuccessfully completed underwritten Pro-Rata Share and Options issueChange of constitution to enable the sale of... (Sydney Morning Herald)
Biopartnering Aug 29, 2008
Affitech discovers and develops fully human antibody therapeutics for both partners, such as Roche and Peregrine, and its own pipeline with a primary focus in oncology ... By discovering both antibody and target simultaneously from patient libraries CBAS shortens development times by up to two years. (Nature News Service)
Novavax says experimental bird flu vaccine works Aug 27, 2008
The Rockville-based company, using technology that can cut the time it takes to manufacture vaccines in half, says the vaccine showed strong antibody activity at three levels of dosing among 160 patients taking part in the clinical trial, with the best response in patients getting the highest dose. The vaccine targets a strain of avian flu that emerged in Indonesia in 2005, and has infected at least 135 humans, most of whom have died. (Washington Business Journal, DC)
Early trigger for type-1 diabetes found in mice, Stanford scientists report Aug 27, 2008
To confirm the signal's nefarious role, the researchers gave mice an antibody that blocks interferon-alpha activity several weeks before the animals were expected to develop diabetes. Thwarting interferon-alpha delayed the start of the disease by an average of four weeks, and, in 60 percent of treated mice, it prevented diabetes entirely. (EurekAlert!)
What makes pancreatic cancer so deadly? Aug 26, 2008
We are also using biologic agents now, meaning antibody therapy. There's a drug called , which is an antibody [or immune protein] against the growth factor that the tumor cell makes, and so it blocks that growth signal. (Scientific American)
Hendra virus review welcomed Aug 22, 2008
" Another case Meanwhile, a north Queensland veterinarian says a horse that has tested positive to Hendra virus at a property near Proserpine should be studied and not put down. It is the third horse on that property to contract the illness, with two put down since July. Dr Mark Williams says the horse shows no signs of sickness and offers the Department of Primary Industries an opportunity to learn more about the rare disease. "You would be isolating it, doing regular blood tests to see if the... (ABC Online)
Adalimumab in Juvenile Rheumatoid Arthritis Aug 21, 2008
We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis. Methods Patients 4 to 17 years of age with active juvenile rheumatoid arthritis who had previously received treatment with nonsteroidal antiinflammatory drugs underwent stratification according to methotrexate use and received 24 mg of adalimumab per square meter of body-surface area (maximum dose, 40 mg) subcutaneously every other... (New England Journal of Medicine)
Hantavirus deaths rare Aug 20, 2008
The state will conduct its own antibody tests to determine if Ng died of hantavirus. Hantavirus was discovered in the United States in 1993 in the Four Corners area of the Southwest. (Ellensburg Daily Record, WA)
Affitech and Omeros Enter Into Antibody Discovery and Development Agreement Aug 19, 2008
SEATTLE and OSLO, Norway, Aug. 19 /PRNewswire/ -- Omeros Corporation, a Seattle-based clinical-stage biopharmaceutical company, and Affitech AS, a Norwegian human antibody therapeutics company, today announced that they have entered into an agreement for the discovery and development of fully human antibodies for Omeros' MASP-2 program ... Affitech will apply its expansive human antibody libraries and proprietary antibody discovery and screening technologies, including its AffiScreen(TM)... (PR Newswire)
Maelstrom Quashes Jumping Genes Aug 19, 2008
By marking the protein with a fluorescent antibody, they found that it was predominantly located in the cytoplasm, near the nucleus of the germ cell, at the nuage. To understand what Maelstrom does during the formation of sperm, the scientists created mutant mice that did not have the gene to produce the Maelstrom protein. (Science Daily)
Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model Aug 17, 2008
Apoptotic cells and vessels were evaluated by fluorescent in situ TUNEL assay and by immunohistochemistry with an antibody reactive to CD31 respectively. Results. (BioMed Central)
Michael J. Fox Foundation Awards One Million Dollars for Development of 'Trojan Horse' Delivery Technology to Treat Parkinson's Disease Aug 16, 2008
The end goal is to create a safe and effective treatment in which GDNF, fused to a genetically engineered antibody that is naturally capable of crossing the blood-brain barrier, can be injected intravenously into the blood. The antibody, "hiding" the GDNF inside itself -- as the Trojan horse of Homer's Iliad hid Greek soldiers, allowing them to enter Troy -- would then ferry the attached GDNF across the blood-brain barrier, from the blood to the target site in brain. (PR Newswire)
Antibody Drug Unleashes Tumor-Killer T Cells Aug 16, 2008
Trial of a two-pronged antibody that attacks late-stage cancer finds it is safe and effective even at relatively low doses ... A biotech company, Micromet, has designed an antibody-based drug that seems to seek out and kill cancer cells ... The technology is only in early human clinical trials, but if it proves effective, this new antibody a protein employed by the immune system to ferret out foreign invaders could offer way to stop non-Hodgkin's lymphomas, a type of cancer, in its tracks. (Scientific American)
Slipping Through Cell Walls, Nanotubes Deliver High-potency Punch To Cancer Tumors In Mice Aug 16, 2008
"But a more active targeting would be attaching a peptide or antibody to the nanotube drug, one that will bind more specifically to the tumor, which should further enhance the treatment efficacy.". Dai's team is already at work developing more targeted approaches, and he is optimistic about the potential applications of nanotubes. (Science Daily)
New Lymphoma Drug Shows Promise Aug 16, 2008
The drug is what its authors call a BiTE, a kind of antibody that flags foreign particles and infected cells for immune clearance ... "The antibody decorates tumor cells so any passing T-cell touching that cell briefly will adhere to it much longer than normal, and then the whole program of cell killing is kicked off," Baeuerle said ... That approach is different from the one used by most antibody therapeutics, which flag diseased cells but do not necessarily recruit T-cells to kill them, Kipps... (MEDLINEplus)
UPDATE: Help Could Be On The Way For Alzheimer's Aug 15, 2008
In late July, shares of Wyeth and Elan were hammered on mixed Phase II news for their highly-touted antibody therapy bapineuzumab ... Lilly is also developing an antibody-based product code-named LY2062430 ... Lilly added that the product, as opposed to some other antibody therapies, did not appear to trigger any treatment-related brain-swelling, bleeding or similar negative side effects. (CNNMoney.com)
Lexicon Pharmaceuticals Identifies New Drug Candidate for Glaucoma Aug 13, 2008
Lexicon has applied small molecule chemistry and antibody technology to these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. Lexicon's goal is to advance 10 drug candidates into human clinical trials by the end of 2010, the strategic objective of its 10TO10 program. (Primezone Releases)
Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic Aug 12, 2008
In addition, the Company is a world leader in the development of novel camelid antibody products to provide unique avenues of progress and improvement in assay methods and monitoring capabilities for physicians, patients and researchers, particularly for food chain protection applications. Canopus maintains staff in Australia, South Africa, Ireland and the USA. Additional information on the Company is available at. (PR Newswire)
DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody Aug 12, 2008
MOR202 is a fully human HuCAL(R) antibody, directed against CD38, a promising target for the treatment of multiple myeloma. DSM Biologics will manufacture MOR202 in its cGMP facilities in Groningen, the Netherlands. (PR Newswire)
PDL BioPharma Q2 profit jumps to $33.9M Aug 12, 2008
The company said the growth was driven by antibody product licensees, particularly South San Francisco-based (NYSE:DNA). Total costs and expenses for the second quarter were $60. (San Jose Business Journal, CA)
Bradmer announces 2008 second quarter operational and financial results Aug 11, 2008
About Neuradiab(TM) Neuradiab is a monoclonal antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer ... Neuradiab has been formerly referred to in literature as 131-I anti-tenascin monoclonal antibody 81c6. (Canada Newswire)
Test Vaccines Show Promise Against Parasite Of Cattle Aug 11, 2008
The scientists found that the serum antibody levels against the protein correlated well with the levels of protection. They also observed that the vaccine containing both NcCyP and NcSRS2 was no more effective than the vaccine that just contained NcCyP. However, more work is needed to evaluate the efficacy of these proteins in protecting cattle--the host animal--against the disease. (Science Daily)
Breakthrough in leukaemia treatment Aug 11, 2008
Drugs which use antibody molecules to disrupt the regulator's work are in development at CSL.. Professor Andrew Roberts, from the Walter and Eliza Hall Institute in Melbourne, said the find was a "major step forward". (Sydney Morning Herald)
RNA stops HIV in its tracks Aug 11, 2008
The research team first neutralised and disguised the siRNA by complexing it with a conjugate consisting of a short peptide chain made of nine positively-charged D-arginine residues and a small antibody that specifically recognises a protein receptor on T-cells. The team used a special mouse model to test the system. (Chemistry World)
New Gene Technique Stops HIV In Its Tracks Aug 10, 2008
In the lab experiments, the study researchers mixed the silenced RNAs with the antibody carriers and injected the mixture into the veins of the animals. The researchers also said that further research has to be done on this subject. (TopNews)
Gene Silencing May Stop AIDS Virus Aug 9, 2008
Now Priti Kumar, PhD, Premlata Shankar, MD, and colleagues have linked siRNA to an antibody that delivers them directly to T cells -- and to a molecule that transports them to the cell nucleus where it can attack HIV genes. They used a siRNA cocktail: two siRNAs that inactivate different HIV genes and one siRNA that keeps T cells from expressing the CCR5 molecule to which HIV attaches. (WebMD)
Persons Tested for HIV --- United States, 2006 Aug 8, 2008
One possible reason for the relatively lower rate of HIV testing among pregnant women is that HIV testing, unlike these others infectious diseases, is not currently included by the American Medical Association as one of the defined components of the obstetric panel Common Procedural Terminology (CPT) code, which includes blood count, HBsAg, rubella antibody, syphilis screen, and blood type and group. Although a greater percentage (21. (Food Consumer)
Researchers Silence HIV in Mice Engineered to Be Like Humans Aug 8, 2008
The team hitched the RNA segments to an antibody a protein that specifically seeks out and attaches to T cells to deliver their cargo ... "It might be that the antibody is not going to get at these other cells, so it might not work without other antiretrovirals.". (Scientific American)
AIDS Breakthrough? HIV Halted With RNAi In Mice Aug 8, 2008
The truck in this case, a single-chain antibody developed by Georg Fey of the University of Erlangen in Germany homed to a protein found exclusively on the surface of T cells ... This new antibody delivery vehicle lends itself to mass production in a dish ... Harvard Medical School postdoctoral researcher and first author Priti Kumar mixed the siRNAs with the antibody carriers and injected them into the veins of mice that harbor human T cells rather than their own. (Science Daily)
MIR Preclinical Services Highlights Offerings At Fall 2008 Conferences Aug 8, 2008
International IRA Conference, September 21st-24th Chantilly, Virginia: MIR will be featuring its services such as Collagen Induced Arthritis (CIA), Collagen Antibody Induced Arthritis (CAIA), Adjuvant Induced Arthritis (AIA), LPS Induced Cytokine Release, Delayed Type Hypersensitivity (DTH), Carrageenan Induced Footpad Edema (CFE), Air Pouch Granuloma and custom models for the evaluation of novel anti-inflammatory agents ... American College of Rheumatology Conference, October 26th-29th San... (Primezone Releases)
Study sees need for standardized evaluation of antibody response to HIV-1 Aug 8, 2008
Polonis and colleagues also found that the clade C antibody pool (from subjects infected with clade C from Tanzania) was broadly cross-reactive, neutralizing the greatest number of viruses in both assays. "The data is encouraging," noted Polonis. (EurekAlert!)
Revolutionary Technique Could Reduce Lifelong Drugs For Transplant Patients Aug 7, 2008
26, 1998) Organ transplant rejection caused by CD4 T cells could be stopped in the future using a new hybrid antibody developed at National Jewish Medical and Research Center. (May 19, 1999) A kidney transplant offers people with kidney failure a new chance at a normal, active life. (Science Daily)
